Literature DB >> 26542163

Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis.

Lucio Manenti1, Augusto Vaglio2, Elisa Gnappi2, Umberto Maggiore2, Landino Allegri2, Marco Allinovi2, Maria L Urban2, Marco Delsante2, Maricla Galetti2, Maria Nicastro2, Francesco P Pilato3, Carlo Buzio2.   

Abstract

BACKGROUND AND OBJECTIVES: Complement alternative pathway (cAP) activation has recently been recognized as a key pathogenic event in ANCA-associated vasculitis (AAV). cAP dysregulation is also a major determinant of thrombotic microangiopathies (TMA), which can in turn complicate AAV. We explored the prognostic significance of cAP activation and of histologic evidence of TMA in a cohort of patients with renal AAV. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 46 patients with AAV diagnosed between January 1990 and December 2011 at the Nephrology Unit of Parma University Hospital; 30 of them had undergone renal biopsy. We analyzed serum levels of C3 (sC3) and C4 (sC4) and, for 19 patients who had frozen plasma, plasma Bb and C5b-9 levels. We also reviewed all kidney biopsy specimens, specifically searching for histologic signs of TMA, and performed immunofluorescence or immunohistochemistry for C3d, C4d, Bb and C5b-9.
RESULTS: sC3 was below the lower limit of normal in 35% of the patients, whereas C4 was low in only 2%. Patients with low sC3 tended to be older (P=0.04) and to have lower eGFR at diagnosis (P=0.06). The median follow-up was 78 months (interquartile range, 18-135 months); 18 patients reached ESRD (10 of 14 and 8 of 26 in the low and normal sC3 groups, respectively). Death-censored renal survival was lower in the low sC3 group than in the normal sC3 group (log-rank test, P=0.01). Eight of the 30 patients who had undergone biopsy (27%) had histologic signs of TMA; these signs were more frequent in patients with low sC3 (5 of 10 versus 3 of 20; P=0.04). Notably, patients with histologic signs of TMA had a dramatically worse death-censored renal survival than patients without TMA (log-rank test, P=0.01), with ESRD occurring in 8 of 8 patients with TMA versus 8 of 22 patients without TMA.
CONCLUSIONS: Low sC3 levels and histologic signs of TMA are associated with a poor renal prognosis in patients with AAV.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  CKD progression; anti-neutrophil cytoplasmic antibody-associated vasculitis antibodies, antineutrophil cytoplasmic biopsy kidney failure, chronic thrombotic microangiopathies; complement; vasculitis

Mesh:

Substances:

Year:  2015        PMID: 26542163      PMCID: PMC4670755          DOI: 10.2215/CJN.00120115

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  18 in total

1.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

2.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  With complements from ANCA mice.

Authors:  Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

4.  C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Authors:  Hong Xiao; Daniel J Dairaghi; Jay P Powers; Linda S Ertl; Trageen Baumgart; Yu Wang; Lisa C Seitz; Mark E T Penfold; Lin Gan; Peiqi Hu; Bao Lu; Norma P Gerard; Craig Gerard; Thomas J Schall; Juan C Jaen; Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

5.  Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.

Authors:  Shen-Ju Gou; Jun Yuan; Chen Wang; Ming-Hui Zhao; Min Chen
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

6.  Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.

Authors:  D Huugen; A van Esch; H Xiao; C J Peutz-Kootstra; W A Buurman; J W Cohen Tervaert; J C Jennette; P Heeringa
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

7.  Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.

Authors:  Danielle Cohen; Marije Koopmans; Idske C L Kremer Hovinga; Stefan P Berger; Marian Roos van Groningen; Gerda M Steup-Beekman; Emile de Heer; Jan Anthonie Bruijn; Ingeborg M Bajema
Journal:  Arthritis Rheum       Date:  2008-08

Review 8.  Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Peiqi Hu; Hong Xiao
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

9.  Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis.

Authors:  J C Jennette; A S Wilkman; R J Falk
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

Review 10.  Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature.

Authors:  Lucio Manenti; Elisa Gnappi; Augusto Vaglio; Landino Allegri; Marina Noris; Elena Bresin; Francesco Paolo Pilato; Elisabetta Valoti; Sonia Pasquali; Carlo Buzio
Journal:  Nephrol Dial Transplant       Date:  2013-06-19       Impact factor: 5.992

View more
  34 in total

1.  Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.

Authors:  Li Huang; Chanjuan Shen; Yong Zhong; Joshua D Ooi; Ya-Ou Zhou; Jin-Biao Chen; Ting Wu; Ting Meng; Zhou Xiao; Wei Lin; Xiang Ao; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Clin Exp Med       Date:  2020-02-20       Impact factor: 3.984

Review 2.  Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives.

Authors:  Lucio Manenti; Maria Letizia Urban; Federica Maritati; Maricla Galetti; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 3.  Complement in ANCA-associated vasculitis: mechanisms and implications for management.

Authors:  Min Chen; David R W Jayne; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-03-20       Impact factor: 28.314

Review 4.  Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.

Authors:  Damien Noone; Diane Hebert; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-09-05       Impact factor: 3.714

Review 5.  Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review.

Authors:  Jon Badiola; Nuria Navarrete-Navarrete; José Mario Sabio
Journal:  Rheumatol Int       Date:  2018-12-15       Impact factor: 2.631

Review 6.  The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.

Authors:  G Trivioli; A Vaglio
Journal:  Clin Exp Immunol       Date:  2020-10-05       Impact factor: 4.330

Review 7.  Novel Therapies for ANCA-associated Vasculitis.

Authors:  Sara Monti; Fabio Brandolino; Alessandra Milanesi; Blerina Xoxi; Paolo Delvino; Carlomaurizio Montecucco
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 8.  Update on ANCA-associated vasculitis: from biomarkers to therapy.

Authors:  Martina Tedesco; Maurizio Gallieni; Francesca Pellegata; Mario Cozzolino; Federico Alberici
Journal:  J Nephrol       Date:  2019-07-12       Impact factor: 3.902

9.  Circulating C3 levels predict renal and global outcome in patients with renal vasculitis.

Authors:  Javier Villacorta; Francisco Diaz-Crespo; Mercedes Acevedo; Teresa Cavero; Carmen Guerrero; Manuel Praga; Gema Fernandez-Juarez
Journal:  Clin Rheumatol       Date:  2016-08-25       Impact factor: 2.980

Review 10.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.